Expert consensus on unmet needs, referral criteria and treatment goals for hidradenitis suppurativa in Saudi Arabia

References

• Rathod U, Prasad PN, Patel BM, et al. Hidradenitis suppurativa: a literature review comparing current therapeutic modalities. Cureus. 2023;15(8):1. doi:10.7759/cureus.43695.
   Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–9. doi:10.1111/jdv.12966.
   PubMed Web of Science ®Google Scholar
• Alsadhan H, Alfawzan AI, Yaqoub A, et al. Hidradenitis suppurativa: estimated prevalence, clinical features, and risk factors in Riyadh, Saudi Arabia. Cureus. 2022;14(3):e23029. doi:10.7759/cureus.23029.
   PubMed Web of Science ®Google Scholar
• Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):7–16. doi:10.1016/j.det.2015.08.002.
   PubMed Web of Science ®Google Scholar
• Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis. Biomed Dermatol. 2020;4(1):2. doi:10.1186/s41702-019-0052-0.
   Google Scholar
• Ooi XT, Choi E, Han H, et al. The psychosocial burden of hidradenitis suppurativa in Singapore. JAAD Int. 2023;10:89–94. doi:10.1016/j.jdin.2022.10.010.
   PubMedGoogle Scholar
• Scholl L, Schneider-Burrus S, Fritz B, et al. The impact of surgical interventions on the psychosocial well-being of patients with hidradenitis suppurativa. J Dtsch Dermatol Ges. 2023;21(2):131–139. doi:10.1111/ddg.14934.
   Google Scholar
• Maghfour J, Sivesind TE, Dellavalle RP, et al. Trends in hidradenitis suppurativa disease severity and quality of life outcome measures: scoping review. JMIR Dermatol. 2021;4(2):e27869. doi:10.2196/27869.
   PubMedGoogle Scholar
• Horváth B, Janse I, Blok J, et al. Hurley staging refined: a proposal by the Dutch hidradenitis suppurativa expert group. Acta Derm Venerol. 2017;97(3):412–413. doi:10.2340/00015555-2513.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831–839. doi:10.1111/j.1365-2133.2009.09198.x.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149(1):211–213. doi:10.1046/j.1365-2133.2003.05390.x.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Chiricozzi A, Giovanardi G, et al. Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore. J Eur Acad Dermatol Venereol. 2020;34(8):1815–1821. doi:10.1111/jdv.16328.
   PubMed Web of Science ®Google Scholar
• Hessam S, Scholl L, Sand M, et al. Distinguishing mild, moderate, and severe hidradenitis suppurativa-reply. JAMA Dermatol. 2018;154(8):972. doi:10.1001/jamadermatol.2018.1600.
   Web of Science ®Google Scholar
• Nesbitt E, Clements S, Driscoll M. A concise clinician’s guide to therapy for hidradenitis suppurativa. Int J Womens Dermatol. 2020;6(2):80–84. doi:10.1016/j.ijwd.2019.11.004.
   PubMedGoogle Scholar
• Hunger RE, Laffitte E, Läuchli S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa. Dermatology. 2017;233(2-3):113–119. doi:10.1159/000477459.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Collier F, Brown D, et al. British association of dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180(5):1009–1017. doi:10.1111/bjd.17537.
   PubMed Web of Science ®Google Scholar
• Johnston LA, Alhusayen R, Bourcier M, et al. Practical guidelines for managing patients with hidradenitis suppurativa: an update. J Cutan Med Surg. 2022;26(2_suppl):2S–24S. doi:10.1177/12034754221116115.
   PubMed Web of Science ®Google Scholar
• Hendricks AJ, Hsiao JL, Lowes MA, et al. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237(1):81–96. doi:10.1159/000503605.
   PubMed Web of Science ®Google Scholar
• Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001–1009. doi:10.1001/jamasurg.2021.3655.
   PubMed Web of Science ®Google Scholar
• Abu Rached N, Gambichler T, Ocker L, et al. Screening for diabetes mellitus in patients with hidradenitis suppurativa-a monocentric study in Germany. Int J Mol Sci. 2023;24(7):6596. doi:10.3390/ijms24076596.
   PubMed Web of Science ®Google Scholar
• Schrader AM, Deckers IE, van der Zee HH, et al. Hidradenitis suppurativa: a retrospective study of 846 dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460–467. doi:10.1016/j.jaad.2014.04.001.
   PubMed Web of Science ®Google Scholar
• Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis – results from a multicenter national prospective study. J Rheumatol. 2014;41(3):490–494. doi:10.3899/jrheum.130977.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546–1549. doi:10.1111/bjd.14038.
   PubMed Web of Science ®Google Scholar
• Garg A, Neuren E, Cha D, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project. J Am Acad Dermatol. 2020;82(2):366–376. doi:10.1016/j.jaad.2019.06.1301.
   PubMed Web of Science ®Google Scholar
• Hidradenitis Suppurativa: early Recognition Improves Prognosis - Medscape - 30. August 2019.
   Google Scholar
• Collier F, Howes R, Rodrigues J, et al. Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. BJGP Open. 2021;5(5):BJGPO.2021.0051. doi:10.3399/BJGPO.2021.0051.
   PubMedGoogle Scholar
• Management of hidradenitis suppurativa: an Australasian consensus statement. Available at: https://dermnetnz.org/topics/hidradenitis-suppurativa-guidelines. Last updated: August 2018.
   Google Scholar
• Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90. doi:10.1016/j.jaad.2019.02.067.
   PubMed Web of Science ®Google Scholar
• Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document. J Cutan Med Surg. 2017;21(6):513–524. doi:10.1177/1203475417716117.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the european guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343–351. doi:10.1007/s11154-016-9328-5.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434–1442. doi:10.1111/bjd.13270.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31. doi:10.1111/jdv.15233.
   PubMed Web of Science ®Google Scholar
• Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf. Accessed on October 05, 2023.
   Google Scholar
• Kohorst JJ, Baum CL, Otley CC, et al. Patient satisfaction and quality of life following surgery for hidradenitis suppurativa. Dermatol Surg. 2017;43(1):125–133. doi:10.1097/DSS.0000000000000942.
   PubMed Web of Science ®Google Scholar
• Finstad A, Lee A, George R, et al. Exploring access to surgical interventions for hidradenitis suppurativa: retrospective population-based analysis. JMIR Dermatol. 2021;4(2):e31047. doi:10.2196/31047.
   PubMedGoogle Scholar
• Shukla N, Paul M, Halley M, et al. Identifying barriers to care and research in hidradenitis suppurativa: findings from a patient engagement event. Br J Dermatol. 2020;182(6):1490–1492. doi:10.1111/bjd.18818.
   PubMed Web of Science ®Google Scholar
• Willems D, Hiligsmann M, van der Zee HH, et al. Identifying unmet care needs and important treatment attributes in the management of hidradenitis suppurativa: a qualitative interview study. Patient. 2022;15(2):207–218. doi:10.1007/s40271-021-00539-7.
   PubMedGoogle Scholar